Monday's rebound faded as chips reversed and two AI companies leaning on new paper fell with them. Apple and Palantir beat after the close. Crude fell nearly 8%, yet December hike odds held near three in four. Binance's reserve proof landed early, dated before it reopened.

MARKET PULSE

The bounce lasted one morning. Chips joined it early, then led the reversal.

The S&P 500 gave up a gain of about 1% to finish down about 0.5%. The semiconductor index rose nearly 2% in the first hour and ended down about 3.4%. The Nasdaq lost about 1.1%, while the Dow rose about 0.4%.

Marvell (MRVL) agreed to buy Lumentum (LITE) for 4.5 Marvell shares each, valued at $1,132 a share on Oct. 28 prices. At Monday's close, the offer was worth about $771. Marvell fell about 13% and Lumentum about 19%.

Oracle (ORCL), down about 9%, filed to sell $10 billion of stock and $10 billion of notes. The amount matches the $20 billion funding cap it set at its investor day five days earlier, a cap that excludes refinancing. AMD (AMD) fell about 7.5% into Tuesday's report, Intel (INTC) about 9% and Micron (MU) about 6%.

After the bell, the two biggest reports beat. Apple (AAPL) earned $2.10 a share on revenue of $114.5 billion, up 12%, both above forecasts. Tariff refunds supplied 5 cents of the profit. Palantir (PLTR) grew revenue 96% to $2.31 billion, and its U.S. commercial sales passed U.S. government sales for the first time. Palantir rose modestly after hours. Apple barely moved.

Beats Barely Moved

Two AI companies leaned on new paper and fell with the whole chip group. After the bell, two beats barely moved their stocks. So far, financing and sector risk are moving prices more than results are.

Premier Feature

WARNING to Anyone Over 50: This Could Be the LAST Great Bull Market of Your Life

Crash warnings are everywhere. Yet Dr. Mark Skousen, the man who called 1987's Black Monday, says stocks could double from here... maybe triple by 2029. It may sound crazy. But the last time he made a call this bold, in January 1995, the Nasdaq went on to rise nearly seven-fold.

Watch his free briefing now. You may not get a chance like this again.

ENERGY

Crude doubled its drop. The fuel market lagged.

U.S. crude fell nearly 8% to about $96 a barrel, roughly twice its morning decline. Reports of a draft proposal circulated after talks in Doha, but there is no deal.

Refined fuels and energy stocks fell far less than crude. Heating oil futures lost about 5.6%. Exxon (XOM) fell about 4%, Chevron (CVX) about 3% and Valero (VLO) about 4.5%. Airlines took the other side, with Delta (DAL) and United (UAL) each up more than 4%.

The bettors swung harder. Polymarket's contract on the U.S.-Iran ceasefire holding through Nov. 15 traded at 66.5 cents in early afternoon, then slipped to about 54 cents late in the day in thin trading. Late Monday, President Trump said "no" when asked whether he was considering strikes after the midterms. He added that a deal "could happen." On the water, little has changed. Tankers have been struck in the past week, and the strait remains restricted.

The Barrel Moved, the Rest Didn’t

Crude moved as if a deal were closer. Fuel prices and energy stocks moved far less, a gap that fits a slower end to supply risk, though producer shares usually lag the commodity. The ceasefire bets have not settled on either reading.

MACRO

Oil lost nearly 8%. The December hike bet barely blinked.

If crude were the engine of the Fed's hiking case, Monday should have dented it. Kalshi's contract on a December quarter-point hike traded at 73 cents in early afternoon, up from 71 cents overnight.

Factories handed the hawks another argument. The ISM manufacturing index rose to 55.5, above the 54.6 forecast. Its production gauge hit 59.0, the highest since November 2021.

The rest argued for patience. ISM's prices index fell 2.7 points to 75.2, below the 77.5 forecast. The Fed's loan officer survey showed weaker demand for business loans, mortgages and auto loans. The 10-year yield slipped to about 4.89%, its lowest since early September.

The Bet Ignored the Barrel

Oil's drop did not move the hike bet. Factory strength now gives the hawks another argument, and Monday's prices index cut against it. Friday's payrolls and the Nov. 10 inflation report test which reading holds.

From Our Partners

Still Using Last Year's Stock List?

A lot of investors are still buying off a "top stocks" list someone made a year ago.

Markets move faster than that.

Our Top 10 Stocks to Buy This Quarter is rebuilt from scratch every quarter. Fresh picks. Fresh reasons. Fresh risks to watch.

See the latest edition, free. →
CAPITAL

Getting money out of private equity is getting harder from both ends.

Investors asked Partners Group's flagship U.S. evergreen fund to redeem about $2.2 billion in the third quarter. The fund accepted $728 million, its 5% cap, and prorated the rest. That is about a third of requests, against about 83% in the second quarter.

The banks are pulling back too. Banks tightened standards on every loan type to nonbank lenders the Fed asked about, private equity funds included. Those funds asked to borrow more anyway.

Valuations are splitting as well. In June, about 12% of borrowers held by more than one business development company carried marks at least five points apart, Frankfurt School research found. A year earlier, it was about 9%.

Rationing, Not Markdowns

One flagship private equity fund met withdrawal requests pro rata, and banks are tightening lending to funds like it. So far, illiquidity is showing up as rationing rather than markdowns, and the marks have started to disagree.

CRYPTO PULSE

Binance delivered its proof a day early. It proves less than the headline.

Holders of 10 tokens, including bitcoin, ether and USDT, can now verify their balances were backed at least one for one. The snapshot is dated Oct. 31, before withdrawals reopened, so it misses the billions customers have pulled since. Binance's disclosed emergency bitcoin wallet holds about 7,500 coins, roughly half its size before last week's transfer.

A second exchange froze withdrawals. Brazil's Mercado Bitcoin suspended deposits and withdrawals after what it called a security incident. Hypernative, a security firm, estimates more than $40 million left its wallets. The exchange says customers lost nothing and has not confirmed an amount. No link to Binance has been established.

Strategy (MSTR) bought 811 bitcoin for $65.5 million last week but spent $208.2 million buying back its STRC preferred stock. With bitcoin near $76,700, its holdings sit less than 2% above their $75,451 average cost. Coinbase (COIN) fell about 4% and touched a new 52-week low.

A Snapshot of a Date Already Gone

Binance proved where it stood on a date that has already passed. Strategy spent three times as much on its own preferred as on the coin. Every check so far describes a moment the market has moved past.

Partner Spotlight

WARNING: A Major Market Shift Could Hit Stocks in 2026

If you have any money in the stock market, you may want to pay attention.

New research points to a massive market-moving event that could send hundreds of popular stocks into a sudden free fall.

Holding the wrong stocks when this hits could erase years of gains.

That’s why analysts have now identified a list of stocks investors may want to avoid as this event unfolds.

If you want to see what’s coming — and which stocks could be most at risk —

Click here to get the full details before it’s too late.

CLOSING LENS

The bounce faded, and chips led it down.

Apple and Palantir beat. Their stocks barely noticed.

One private equity fund rationed withdrawals while banks lent to funds more carefully.

Binance proved Oct. 31. Its customers live in November.

The midterms, AMD and Binance's expected wider reopening come Tuesday. Circle (CRCL) reports Wednesday, and payrolls close the week.

Oil got cheaper on Monday. Bank credit got harder to get.

AI Found the Target. AI Designed the Drug. Now It's in Phase III.

For years, AI drug discovery had a problem. Plenty of models. Very few medicines.
That's changing. One company says AI identified the biological target and then designed the molecule to hit it. In September, the first patient in its Phase III trial was dosed.
It isn't alone. A second AI-engineered medicine is in Phase III, and Big Pharma is now paying for the technology.
We profiled the 5 companies pushing AI into real drug development in a new FREE Special Report: AI Moves Into the Biotech Lab.
We'll text it straight to your phone.

Get the Free Report by Text →